Drugs / Lepodisiran
Lepodisiran
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06916078 | Apr 2025 → Jul 2026 overdue | liver disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05932446 | Jun → Nov 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05841277 | Apr 2023 → Jan 2024 | impaired renal function disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04914546 | Jun 2021 → Nov 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05565742 | Oct 2022 → Oct 2023 | inherited lipid metabolism disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT07613294 | Jun 2026 → Apr 2029 expected | atherosclerosis, lipoprotein, variant of beta | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06292013 | Mar 2024 → Mar 2029 expected | atherosclerotic cardiovascular disease, lipoprotein, variant of beta | Eli Lilly and Company | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-03-30 | Eli Lilly and Company | Results Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels lilly.com ↗
In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the primary endpoint.i |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-03-30 | Eli Lilly and Company | Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels lilly.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lepodisiran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07613294 ↗ |
| Known as | LY-3819469 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068445 ↗ |
| Known as | LY3819469 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05841277 ↗ |
| Route | Subcutaneous | “LY3819469 administered subcutaneously (SC) to participants with normal renal function” NCT05841277 ↗ |